Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two randomized controlled trial(s). ^[1-2]
• Among evaluable patients (mean age 63.7 ± 9.5 years; 32.5% women; 52.3% with Body Mass Index (BMI) ≥ 30 kg/m²), flurpiridaz Positron Emission Tomography (PET) showed higher sensitivity (80.3%) than Single Photon Emission Computed Tomography (SPECT) (68.7%; P = 0.0003), with noninferior specificity (63.8% vs. 61.7%; P = 0.0004); the Area Under the Receiver Operating Characteristic (ROC) curve was greater for flurpiridaz PET (0.80 vs. 0.68; P < 0.001).
• Among evaluable patients (mean age 62.3 ± 9.5 years; 31% women; 55% with BMI ≥ 30 kg/m²; 71% undergoing pharmacological stress), flurpiridaz PET had higher sensitivity (71.9% [95% Confidence Interval (CI): 67.0%–76.3%]) than SPECT (53.7% [95% CI: 48.5%–58.8%]; P < 0.001), but specificity (76.2% [95% CI: 71.8%–80.1%]) did not meet noninferiority to SPECT (86.6% [95% CI: 83.2%–89.8%]; P = Not Significant [NS]); flurpiridaz PET showed superior ROC performance in the overall population, women, obese patients, and those undergoing pharmacological stress (P < 0.001 for all).
• Flurpiridaz PET was reported to be safe and well tolerated, with no significant safety concerns or adverse effects mentioned.